Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, et al
SUSTAIN-6 was pivotal, revealing a 26% reduction in adverse heart outcomes
It is approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, to support longterm weight management in adults and adolescents with obesity or adults with overweight plus comorbidities, and to treat noncirrhotic MASH with moderate to advanced fibrosis in adults under an accelerated approval pathway
As we explore the following drivers of launch success, well highlight how each of these competitors captured share in their respective market
Yes, it can affect both gallbladder function and pancreatic function Hi Dr
Is it ruined